Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital

Digestive Diseases and Sciences

Volumn 55, Issue 12, 2010, Pages 3541-3547

  Yan, Kenneth Kar Lung ^a   Wong, Grace Lai Hung ^a   Wong, Vincent Wai Sun ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Asia; Hepatitis C; Hong Kong; Treatment

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; AGE; ALCOHOL ABUSE; ANTIVIRAL THERAPY; ARTICLE; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEPATITIS C; HONG KONG; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TERTIARY HEALTH CARE; TREATMENT REFUSAL;

ADULT; AGED; ANTIVIRAL AGENTS; COMORBIDITY; FEMALE; HEPATITIS C, CHRONIC; HONG KONG; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 78649325848     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1412-1     Document Type: Article

References (29)

1. T Poynard MF Yuen V Ratziu CL Lai 2003 Viral hepatitis C Lancet 362 9401 2095 2100 1:CAS:528:DC%2BD3sXpvFylsb0%3D 10.1016/S0140-6736(03)15109-4 14697814
2. CW Shepard L Finelli MJ Alter 2005 Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 9 558 567 10.1016/S1473-3099(05)70216-4 16122679
3. N Leung C Chu JS Tam 2006 Viral hepatitis C in Hong Kong Intervirology 49 1-2 23 27 10.1159/000087259 16166785
4. ML Volk R Tocco S Saini AS Lok 2009 Public health impact of antiviral therapy for hepatitis C in the United States Hepatology 50 6 1750 1755 10.1002/hep.23220 19824079
5. M Wise S Bialek L Finelli BP Bell F Sorvillo 2008 Changing trends in hepatitis C-related mortality in the United States, 1995-2004 Hepatology 47 4 1128 1135 10.1002/hep.22165 18318441
6. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 9286 958 965 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5 11583749
7. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 13 975 982 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
8. G Sroczynski E Esteban A Conrads-Frank, et al. 2010 Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C J Viral Hepat 17 1 34 50 1:STN:280:DC%2BC3c%2FhtVGmsA%3D%3D 10.1111/j.1365-2893. 2009.01147.x 19656290
9. SL George BR Bacon EM Brunt, et al. 2009 Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients Hepatology 49 3 729 738 1:CAS:528:DC%2BD1MXjvFOnurY%3D 10.1002/hep.22694 19072828
10. JG McHutchison GT Everson SC Gordon, et al. 2009 Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 18 1827 1838 1:CAS:528:DC%2BD1MXlsVGmtrc%3D 10.1056/NEJMoa0806104 19403902
11. JG McHutchison SC Gordon ER Schiff, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group N Engl J Med 339 21 1485 1492 1:CAS:528:DyaK1cXnslGmtbs%3D 10.1056/NEJM199811193392101 9819446
12. Y Falck-Ytter H Kale KD Mullen, et al. 2002 Surprisingly small effect of antiviral treatment in patients with hepatitis C Ann Intern Med 136 4 288 292 1:CAS:528:DC%2BD38XhvF2ktLo%3D 11848726
13. R Moirand M Bilodeau S Brissette J Bruneau 2007 Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage Can J Gastroenterol 21 6 355 361 17571168
14. AA Butt AC Justice M Skanderson, et al. 2007 Rate and predictors of treatment prescription for hepatitis C Gut 56 3 385 389 10.1136/gut.2006.099150 17005764
15. F Kanwal T Hoang BM Spiegel, et al. 2007 Predictors of treatment in patients with chronic hepatitis C infection-Role of patient versus nonpatient factors Hepatology 46 6 1741 1749 1:CAS:528:DC%2BD2sXhsVGiur7E 10.1002/hep.21927 18046707
16. KK Yan M Guirgis T Dinh, et al. 2008 Treatment responses in Asians and Caucasians with chronic hepatitis C infection World J Gastroenterol 14 21 3416 3420 10.3748/wjg.14.3416 18528940
17. MG Ghany DB Strader DL Thomas LB Seeff 2009 Diagnosis, management, and treatment of hepatitis C: An update Hepatology 49 4 1335 1374 1:CAS:528:DC%2BD1MXkslWjs7o%3D 10.1002/hep.22759 19330875
18. GW McCaughan M Omata D Amarapurkar, et al. 2007 Asian Pacific Association for the study of the liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection J Gastroenterol Hepatol 22 5 615 633 1:STN:280:DC%2BD2s3js1Cmuw%3D%3D 10.1111/j.1440-1746.2007.04883.x 17444847
19. CH Cawthorne KR Rudat MS Burton, et al. 2002 Limited success of HCV antiviral therapy in United States veterans Am J Gastroenterol 97 1 149 155 10.1111/j.1572-0241.2002.05439.x 11808940
20. SK Roberts MD Weltman DH Crawford, et al. 2009 Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial Hepatology 50 4 1045 1055 1:CAS:528:DC%2BD1MXhtlWlu7jM 10.1002/hep.23130 19676125
21. JB Wong RS Koff 2000 Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis Ann Intern Med 133 9 665 675 1:STN:280: DC%2BD3M%2FivFKltQ%3D%3D 11074899
22. S Deuffic-Burban G Babany I Lonjon-Domanec, et al. 2009 Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France Hepatology 50 5 1351 1359 1:CAS:528:DC%2BD1MXhsV2jsrfE 10.1002/hep.23159 19676130
23. Y Iwasaki H Ikeda Y Araki, et al. 2006 Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C Hepatology 43 1 54 63 1:CAS:528:DC%2BD28Xpt1Sgsw%3D%3D 10.1002/hep.20984 16374855
24. R Koyama Y Arase K Ikeda, et al. 2006 Efficacy of interferon therapy in elderly patients with chronic hepatitis C Intervirology 49 3 121 126 1:CAS:528:DC%2BD28XmsFGhsA%3D%3D 10.1159/000089372 16428887
25. CF Huang JF Yang CY Dai, et al. 2010 Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C J Infect Dis 201 5 751 759 1:CAS:528:DC%2BC3cXkt1amtLw%3D 10.1086/650470 20102281
26. G Antonucci MA Longo C Angeletti, et al. 2007 The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr Am J Gastroenterol 102 7 1383 1391 1:CAS:528:DC%2BD2sXoslGlt7k%3D 10.1111/j.1572-0241.2007.01201.x 17403072
27. Y Arase K Ikeda F Suzuki, et al. 2007 Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C Intervirology 50 1 16 23 1:CAS:528:DC%2BD28XhtlSrs7rP 10.1159/000096308 17164553
28. JF Huang ML Yu CM Lee, et al. 2007 Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: A 1,386-patient study from Taiwan Aliment Pharmacol Ther 25 9 1029 1037 1:CAS:528:DC%2BD2sXmsFars7w%3D 10.1111/j.1365-2036.2007.03297.x 17439503
29. OS Khokhar JH Lewis 2007 Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 52 5 1168 1176 10.1007/s10620-006-9579-1 17357838